A
Adimab
Antibody discovery and optimization platform, developing full-length human immunoglobulin gs
About Adimab
Adimab is a biotechnology startup that operates in the pharmaceutical industry, specifically in the field of therapeutic antibody discovery and optimization. The company uses a proprietary platform that combines in vitro and in vivo discovery methods with engineered yeast to develop therapeutic leads. These leads are then refined and improved to create best-in-class molecules.
Read full description
Adimab's business model is based on partnerships. The company works with other businesses in the pharmaceutical and biotech industries, providing them with the tools and technology to discover and optimize their own lead candidates. This is done through a full implementation of the Adimab Platform, which is integrated into the partner's existing workflow.
The company's main source of revenue comes from these partnerships. Adimab makes money by licensing its platform and technologies to its partners, who then use these tools to develop their own therapeutic antibodies. The company also offers a variety of bispecific formats that cover a wide range of biological functionality, further expanding its potential market and revenue streams.
In summary, Adimab is a biotech company that uses its proprietary platform to discover and optimize therapeutic antibodies. It operates in the pharmaceutical industry, serving other businesses in the sector by providing them with the tools and technology to develop their own therapeutic leads. The company makes money through licensing its platform and technologies to its partners.
At a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Lebanon, United States
- Employees
- 136
- Open positions
- 4
- Dealroom signal
- 70.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2021
- Capital deployed
- $336M
- Preferred round
- SERIES C
Latest news
Press, funding announcements and product moves mentioning Adimab.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2020 | $50M | $200M | Undisclosed | — |
| FundingOther financing | Jan 2020 | $0 | — | Lux Capital | — |
Growth signals
Latest recorded traffic for Adimab is 4.7K monthly website visits, up 6.8% over the last three months. Adimab's team declined 2.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Polaris Partners
SV Health Investors- BVBorealis Ventures
OrbiMed
GV
Other known investors3 additional known investors
Dartmouth College
Lux Capital
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adimab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adimab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.